Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration for your bookings.
Abstract Categories 1a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance) 1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance) 1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts) 1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (all aspects) 1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1i. Other 2a. Tuberculosis and other mycobacterial infections (incl antimycobacterial drugs, treatment & susceptibility/resistance, diagnostics & epidemiology) 2b. Severe sepsis, bacteraemia & endocarditis (incl host bio-markers) 2c. Community-acquired respiratory infections 2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections 2e. Skin, soft tissue, bone & joint (excl prostheses) & central nervous system infections 2f. Zoonotic bacterial diseases (incl foodborne and waterborne pathogens and One Health aspects) 2g. Other intracellular or rare bacteria 2h. Other 3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives 3b. Resistance surveillance & epidemiology: Gram-negatives 3c. Susceptibility testing methods (incl assay validation and comparative studies, excl TB) 3d. Resistance mechanisms (excl TB) 3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods) 3f. Clinical outcome of resistant infections (excl trials of new drugs) 3g. Spread of resistance incl reservoirs, ecology, mobile elements (excl nosocomial transmission) 3h. Other 4a. Diagnostic bacteriology – culture based and general microbiology 4b. Lab management, automation and QC 4c. MALDI-TOF and other proteomic methods 4d. Molecular diagnostics (incl POCT and syndromic testing) 4e. Strain typing and surveillance (methods other than genomics) 4f. Whole genome sequencing (diagnostic, typing) 4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects) 4h. Clinical metagenomics 4i. Bioinformatics tools & pipelines 4j. Other 5a. Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents 5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring 5c. New or repurposed antibacterial agents: clinical trials 5d. Pharmacoepidemiology (incl economics and cost-effectiveness), improved prescribing and antibiotic stewardship (incl decision-support / prediction tools, behavioural aspects) 5e. Safety and adverse effects of treatment 5f. Other 6a. Fungal disease epidemiology 6b. Diagnostic mycology (incl molecular) 6c. Antifungal drugs & treatment (incl clinical trials) 6d. Antifungal resistance & susceptibility testing (incl surveillance) 6e. Other 7a. Diagnostic parasitology 7b. Antiparasitic susceptibility & resistance 7c. Antiparasitic drugs & treatment 7d. Parasitic disease epidemiology 7e. Travel medicine & migrant health 7f. Food & water safety and environmental health 7g. International & public health 7h. Other 8a. Intravascular catheter-related infections 8b. Other foreign-body and implant infections 8c. Surgical site infections 8d. Healthcare-associated pneumonia 8e. Hospital epidemiology, transmission, surveillance & screening (incl. environment) 8f. Other healthcare associated infections (incl CDI) 8g. Infection control interventions and trials (incl. microbiota transplantation) 8h. Disinfection & biocides 8i. Other 9a. Microbial pathogenesis & virulence 9b. Host-pathogen interaction (including basic microbiome studies) 9c. Preclinical biofilm studies 9d. Experimental and cellular microbiology 9e. Other 10a. Host genetics: infection susceptibility & immunodeficiency 10b. Clinical epidemiology and treatment of infections in immunocompromised hosts 10c. General vaccinology (incl. policy, social aspects) 10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses) 10e. Antibacterial vaccines 10f. Immune response to infection (excl sepsis biomarkers) 10g. Other 11a. Education and career 11b. Publishing, ethics, other academic and professional affairs 11c. Other 12a. Basic science and virology 12b. Epidemiology- local, regional, global 12c. Clinical features, case management, outcome 12d. Diagnostics 12e. Drug development and treatment modalities (incl. clinical trials) 12f. Immune response, immunomodulation 12g. Vaccine development and trials 12h. Infection control 12i. Public health policy, mitigation 12j. Preparedness and response 12k. Other societal aspects (incl. economics) 12l. Other 21. New drugs 22. Clinical trials 23. COVID-19 24. Outbreaks and public health emergencies other than COVID-19 25. Other
